Oral Ribavirin Treatment Failure for Severe Parainfluenza Type 1 Infection in a Patient with End Stage Intstitial Lung Disease Successfully Treated with DAS181

Bogdanovich T1, Kwak EJ1, Silveira FP1, Pakstis DL1, Lanza P2*, and Moss RB2

1Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA
2Ansun Biopharma, Inc., San Diego, CA, USA

*Correspondence author: Lanza P, Ansun Biopharma, Inc., 3030 Callan Road, San Diego CA 92121, USA, Tel: 858-452-2631; Fax: 858-452-0133; E-mail: planza@ansunbiopharma.com

Received date: January 27, 2016; Accepted date: February 18, 2016; Published date: February 28, 2016

Abstract

Parainfluenza virus (PIV) infections can cause serious respiratory infections and death in immunocompromised patients. No antiviral drugs have proven efficacy against PIV. DAS181, a sialidase fusion protein has been shown to inhibit infection with PIV strains both in vitro and in animal model. The clinical course of immunocompromised patients with PIV-1 infection is described. After being diagnosed with PIV infection, patient was treated for 18 days with oral Ribavirin (RBV) but failed to respond clinically and no virus clearance was obtained. However, patient tested negative for PIV after a 10-days DAS181 treatment course. This case exemplifies failure of oral RBV treatment of severe Parainfluenza virus infection and subsequent viral clearance associated with administration of inhaled DAS181. Large scale randomized trials are warranted to determine the therapeutic efficacy of DAS181 against PIV related lung disease.

Abbreviations

ALT: Alanine Transaminase; AST: Aspartate transaminase; FDA: Food and Drug Administration; HCT: Hematopoietic Cell Transplant; IND: Investigational New Drug; NP: Nasopharyngeal; PIV: Parainfluenza Virus; RBV: Ribavirin; RVP: Respiratory Viral Panel

Keywords: DAS181; Parainfluenza virus; Hematopoietic cell transplant; Sialidase; Immunocompromised; Resistance

Case Report

The patient was a 24 year old man listed for double lung transplantation for end stage interstitial lung disease due to systemic scleroderma. He initially presented to an outside medical center with hypoxemic respiratory failure; he was maintained on 100% oxygen high flow nasal cannula alternating with a non-rebreather mask and Bilevel Positive Airway Pressure as needed. He was found to have Parainfluenza type 1 (PIV-1) infection based on nasopharyngeal (NP) swab testing. He was started on oral Ribavirin (400 mg PO TID for 3 days) and received IVIG for 3 days without clinical improvement. He was transferred to our center in consideration for possible lung transplantation and required intubation and tandem Heart placement for new right heart failure on the second day after his transfer. Chest X-ray on admission showed pneumonia (Figure 1). His NP swab on admission was still positive for PIV-1 (Figure 2) and the patient was made inactive on the lung transplant list. A bronchoalveolar lavage bacterial culture obtained on admission was negative but he was kept on empiric antibacterial therapy with piperacillin/tazobactam. He was continued on oral Ribavirin (400 mg PO TID) for additional 15 days but remained persistently positive for PIV-1 on NP swabs (Figure 2).

Due to lack of clinical or virological response, Ribavirin was discontinued after a total of 18 days and the patient was started on the investigational antiviral agent DAS181 [1] under an emergency IND approved by the U.S. FDA. He received DAS181 daily via nebulizer for a complete 10 day treatment course. On day 1 and day 2 he received 1.9 and 3.2 mg of DAS181, respectively. Starting on day 3 until completion of treatment, patient received 4.5 mg of DAS181. DAS181 was well tolerated and his oxygen requirement decreased from 12 L/min to 8L/min while on therapy. On the 8th day of DAS181...
treatment he developed mild elevation of liver enzymes, which peaked at ALT 229 IU/L, AST 304 IU/L, and alkaline phosphatase 224 IU/L. Of note the patient had elevated liver enzymes at the beginning of his admission, prior to therapy with DAS181. The elevation of liver enzymes prior to treatment had been attributed to right ventricular dysfunction and liver congestion and it had normalized prior to administration of DAS181. An NP swab on the 10th day of DAS181 treatment was negative for PIV by Respiratory Viral Panel (RVP) PCR (Figure 2). During the treatment course the patient’s immune suppression regimens and immune status remained stable with his lymphocyte count on admission was 1.3x10⁹/L and 2.0x10⁹/L on the day of death.

Unfortunately, the patient developed new left-sided heart failure compounding right ventricular failure as described above and was determined to be not a suitable candidate for heart-lung transplantation despite clearance of his PIV-1 infection. It was felt that cardiac disease could be due to underlying scleroderma. The patient was placed on comfort care and passed away on day 30 of his transfer and 4 days after completion of therapy with DAS181. An autopsy limited to the lungs and heart was performed and showed diffuse pneumonia in background of hemorrhage with thromboclinically occluded vessels and patchy necrosis overlying extensive fibrinous parenchymal replacement and findings of scleroderma-related cardiac disease. Post-mortem lung cultures showed rare Staphylococcus aureus and a respiratory virus panel on the autopsy lung tissue was negative for PIV-1 by RVP.

Treatment or prevention options for patients with PIV infections are limited as there are no FDA approved antivirals or vaccines. Ribavirin has shown both in vitro and in vivo activity against PIV and is often used for the treatment of PIV [2-4]; however, retrospective studies in the hematopoietic cell transplant (HCT) patients have not shown it to be efficacious in terms of viral shedding, symptom duration, hospital stay, progression or mortality [5-7]. There are very few drugs under development for the treatment of PIV infection [8]. DAS181 is a sialidase catalytic domain/amphiregulin glycosaminoglycan binding sequence fusion protein that enzymatically cleaves the sialic acid residues from the respiratory epithelial cell surface that are essential for viral entry and infection [9]. It has shown efficacy against PIV in vitro, as well as in a cotton rat infection model [10,11]. DAS181 had been used in 3 immunocompromised patients with respiratory infections, including 2 HCT recipients with PIV infection [12,13]. Nebulized DAS181 was successful in clearing the infection from 2 HCT recipients with severe PIV low respiratory tract infections requiring mechanical ventilation; however, 1 of the patients developed recurrent PIV infection at the end of treatment and died [14].

This case exemplifies failure of oral RBV treatment of severe Parainfluenza virus infection and subsequent viral clearance associated with administration of inhaled DAS181 despite continued immunosuppression. A randomized placebo controlled trial examining DAS181 for the treatment of PIV in immunocompromised patients is currently underway.

**Acknowledgement**

Ansun Biopharma, Inc. supplied the DAS181 for this case. R.B. Moss and P. Lanza are employees of Ansun Biopharma, Inc., the manufacturer of DAS181. The other authors have no other conflicts of interest to report.

**References**